Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Blood

• Publication date

  2013-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2013-12-544957PMID 24652988
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

  2013cited by this paper
• Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial

  2013cited by this paper
• Bivalent promoter marks and a latent enhancer may prime the leukaemia oncogene LMO1 for ectopic expression in T-cell leukaemia

  2013cited by this paper
• Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia

  2013cited by this paper
• Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

  2012cited by this paper
• Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial.

  2012cited by this paper
• Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-.

  2012cited by this paper
• The EBMT risk score

  2012cited by this paper
• Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.

  2012cited by this paper
• A novel hierarchical prognostic model of AML solely based on molecular mutations.

  2012cited by this paper
• Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation.

  2012cited by this paper
• Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.

  2012cited by this paper
• TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.

  2012cited by this paper
• Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

  2011cited by this paper
• Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation.

  2011cited by this paper
• Monosomal karyotype provides better prognostic prediction after allogeneic stem cell transplantation in patients with acute myelogenous leukemia.

  2011cited by this paper
• Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.

  2010cited by this paper
• Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A.

  2010cited by this paper
• Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

  2009cited by this paper
• The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia

  2009cited by this paper
• TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis

  2009cited by this paper
• Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

  2008cited by this paper
• Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.

  2008cited by this paper
• Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

  2007cited by this paper
• Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.

  2007cited by this paper
• Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

  2005cited by this paper
• Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

  2003cited by this paper
• Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

  2000cited by this paper
• Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

  2000cited by this paper

• TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation

  2025cites this paper
• Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with ≥5% blasts: An International TP53 Investigators Network (iTiN) study

  2025cites this paper
• Curing the Incurable: TP53 Mutated Myeloid Neoplasms.

  2025cites this paper
• Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From EBMT ALWP

  2025cites this paper
• Prognostic factors for survival after allogeneic transplantation in acute myeloid leukemia in Iran using censored quantile regression model

  2025cites this paper
• Rapid Detection of PML::RARA Fusions in Acute Promyelocytic Leukemia: CRISPR/Cas9 Nanopore Sequencing with Adaptive Sampling

  2024cites this paper
• Biologic and Clinical Characteristics of Isochromosome der(17)(q10)t(15;17) in Acute Promyelocytic Leukemia

  2024cites this paper
• The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy

  2024cites this paper
• Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy

  2023cites this paper
• Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML

  2023cites this paper
• A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

  2023cites this paper
• A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy

  2023cites this paper
• Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

  2023cites this paper
• Pretreatment of umbilical cord derived MSCs with IFN-γ and TNF-α enhances the tumor-suppressive effect on acute myeloid leukemia.

  2022cites this paper
• Transplant for TP53-mutated MDS and AML: because we can or because we should?

  2022cites this paper
• Mutation of the TP53 gene in acute lymphoblastic leukemia does not affect survival outcomes after haploidentical hematopoietic stem cell transplantation

  2022cites this paper
• Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high risk acute myeloid leukemia or myelodysplastic syndrome.

  2021cites this paper
• Post-Transplant Maintenance Therapy for Patients with Acute Myeloid Leukemia: Current Approaches and the Need for More Trials

  2021cites this paper
• Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

  2021cites this paper
• Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy

  2021cites this paper
• The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia

  2021cites this paper
• BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

  2021cites this paper
• Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.

  2020cites this paper
• Title: Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission.

  2020cites this paper
• Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

  2020cites this paper
• Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness

  2020cites this paper
• Recent advances in allogeneic hematopoietic cell transplantation for acute myeloid leukemia.

  2020cites this paper
• Tumor protein 53 mutations in acute myeloid leukemia: conventional induction chemotherapy or novel therapeutics.

  2020cites this paper
• Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste.

  2020cites this paper
• Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*

  2020cites this paper
• Functional Classification of TP53 Mutations in Acute Myeloid Leukemia

  2019cites this paper
• Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group.

  2019cites this paper
• Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations

  2019cites this paper
• TP53 and therapy-related myeloid neoplasms.

  2019cites this paper
• Achievements and Challenges in Allogeneic Hematopoietic Stem Cell Transplantation in Cytogenetically Unfavorable Acute Leukemias (Literature Review)

  2019cites this paper
• Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome

  2019cites this paper
• The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy

  2019cites this paper
• The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA‐matched allogeneic stem cell transplantation

  2019cites this paper
• Significance of Cytogenetics in Leukemia Diagnostics

  2018cites this paper
• Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.

  2018cites this paper
• Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia

  2018cites this paper
• Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.

  2017cites this paper
• The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications

  2017cites this paper
• Antineoplastic effects of CPPTL via the ROS/JNK pathway in acute myeloid leukemia

  2017cites this paper
• Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning

  2017cites this paper
• Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17.

  2017cites this paper
• Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

  2017cites this paper
• Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma.

  2016cites this paper
• Treatment of Acute Myeloid Leukemia in Elderly Patients-A Therapeutic Dilemma.

  2016cites this paper
• Acute myeloid leukemia with TP 53 germline mutations

  2016cites this paper
• Acute myeloid leukemia with TP53 germ line mutations.

  2016cites this paper
• TP53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

  2016cites this paper
• Longitudinal analyses of leukemia-associated antigen-specific CD8+ T cells in patients after allogeneic stem cell transplantation.

  2016cites this paper
• Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.

  2016cites this paper
• Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways

  2015cites this paper
• Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?

  2015cites this paper
• How I treat the older patient with acute myeloid leukemia.

  2015cites this paper
• How I Treat How I treat the older patient with acute myeloid leukemia

  2015cites this paper
• Rational Combinations of Targeted Agents in AML

  2015cites this paper
• Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia

  2015cites this paper
• Cytogenetic abnormalities in Acute Myeloid Leukemia in Sweden. A population based study.

  2015cites this paper
• Preview : Published ahead of advance online publication Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia

  2015cites this paper
• Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.

  2015cites this paper
• Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis

  2015cites this paper
• Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

  2015cites this paper
• Comment on Middeke Et Al, Page 2960

  2014cites this paper
• Abnl(17p) in AML: who will guard the guardian?

  2014cites this paper